References
1. Bonosi L, Marrone S, Benigno UE, et al. Maximal Safe Resection in Glioblastoma Surgery: A Systematic Review of Advanced Intraoperative Image-Guided Techniques. Brain Sci . 2023;13(2):216. doi:10.3390/brainsci13020216
2. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev APJCP . 2017;18(1):3-9. doi:10.22034/APJCP.2017.18.1.3
3. Chen B, Chen C, Zhang Y, Xu J. Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017. BMC Cancer . 2021;21(1):54. doi:10.1186/s12885-020-07778-1
4. Rabab’h O, Al-Ramadan A, Shah J, Lopez-Negrete H, Gharaibeh A. Twenty Years After Glioblastoma Multiforme Diagnosis: A Case of Long-Term Survival. Cureus . 13(6):e16061. doi:10.7759/cureus.16061
5. Matsui JK, Perlow HK, Facer BD, et al. Radiotherapy for elderly patients with glioblastoma: an assessment of hypofractionation and modern treatment techniques. Chin Clin Oncol . 2022;11(5):38-38. doi:10.21037/cco-22-76
6. Chahal M, Thiessen B, Mariano C. Treatment of Older Adult Patients with Glioblastoma: Moving towards the Inclusion of a Comprehensive Geriatric Assessment for Guiding Management. Curr Oncol . 2022;29(1):360-376. doi:10.3390/curroncol29010032
7. Colopi A, Fuda S, Santi S, et al. Impact of age and gender on glioblastoma onset, progression, and management. Mech Ageing Dev . 2023;211:111801. doi:10.1016/j.mad.2023.111801
8. Sun T, Plutynski A, Ward S, Rubin JB. An integrative view on sex differences in brain tumors. Cell Mol Life Sci . 2015;72(17):3323-3342. doi:10.1007/s00018-015-1930-2
9. Wu F, Chai RC, Wang Z, et al. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles. Carcinogenesis . 2019;40(7):853-860. doi:10.1093/carcin/bgz032
10. Zhang P, Xia Q, Liu L, Li S, Dong L. Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy. Front Mol Biosci . 2020;7. Accessed November 28, 2023. https://www.frontiersin.org/articles/10.3389/fmolb.2020.562798
11. Sturm D, Bender S, Jones DTW, et al. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer . 2014;14(2):92-107. doi:10.1038/nrc3655
12. Miller JJ, Loebel F, Juratli TA, et al. Accelerated progression of IDH mutant glioma after first recurrence. Neuro-Oncol . 2019;21(5):669-677. doi:10.1093/neuonc/noz016
13. Șerban G, Tămaș F, Bălașa R, Manu D, Tămaș C, Bălașa A. Prognostic Factors of Survival in Glioblastoma Multiforme Patients—A Retrospective Study. Diagnostics . 2022;12(11):2630. doi:10.3390/diagnostics12112630
14. Manrique-Guzmán S, Herrada-Pineda T, Revilla-Pacheco F. Surgical Management of Glioblastoma. In: De Vleeschouwer S, ed.Glioblastoma . Codon Publications; 2017. Accessed November 28, 2023. http://www.ncbi.nlm.nih.gov/books/NBK469999/
15. Zaresharifi N, Karimzadhagh S, Ebrahimian R, et al. Successful management of a giant retroperitoneal ancient schwannoma mimicking malignant tumors: A case report and literature review. Ann Med Surg .:10.1097/MS9.0000000000001445. doi:10.1097/MS9.0000000000001445
16. Vomer RP, Narducci D, Larick RS, York E, Terry K. Strike Out: A Case Report of Glioblastoma in a Collegiate Softball Player. Cureus . 2023;15(8):e44486. doi:10.7759/cureus.44486
17. Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist . 2021;4(1):17-43. doi:10.20517/cdr.2020.79
18. Ius T, Sabatino G, Panciani PP, et al. Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic review. J Neurooncol . 2023;162(2):267-293. doi:10.1007/s11060-023-04274-x
19. Cruz N, Herculano-Carvalho M, Roque D, et al. Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma.Pharmaceutics . 2023;15(3):928. doi:10.3390/pharmaceutics15030928
20. Boltman T, Meyer M, Ekpo O. Diagnostic and Therapeutic Approaches for Glioblastoma and Neuroblastoma Cancers Using Chlorotoxin Nanoparticles. Cancers . 2023;15(13):3388. doi:10.3390/cancers15133388
21. Yalamarty SSK, Filipczak N, Li X, et al. Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM).Cancers . 2023;15(7):2116. doi:10.3390/cancers15072116
22. Qi D, Li J, Quarles CC, Fonkem E, Wu E. Assessment and prediction of glioblastoma therapy response: challenges and opportunities.Brain . 2023;146(4):1281-1298. doi:10.1093/brain/awac450
23. Cuschieri S. The STROBE guidelines. Saudi J Anaesth . 2019;13(Suppl 1):S31-S34. doi:10.4103/sja.SJA_543_18
24. Hariri L, Rehman A. Estradiol. In: StatPearls . StatPearls Publishing; 2023. Accessed December 6, 2023. http://www.ncbi.nlm.nih.gov/books/NBK549797/
25. Stabellini N, Krebs H, Patil N, Waite K, Barnholtz-Sloan JS. Sex Differences in Time to Treat and Outcomes for Gliomas. Front Oncol . 2021;11:630597. doi:10.3389/fonc.2021.630597
26. Yang W, Warrington NM, Taylor SJ, et al. Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data. Sci Transl Med . 2019;11(473). doi:10.1126/scitranslmed.aao5253
27. Carrano A, Juarez JJ, Incontri D, Ibarra A, Cazares HG. Sex-Specific Differences in Glioblastoma. Cells . 2021;10(7):1783. doi:10.3390/cells10071783
28. Bello-Alvarez C, Camacho-Arroyo I. Impact of sex in the prevalence and progression of glioblastomas: the role of gonadal steroid hormones.Biol Sex Differ . 2021;12(1):28. doi:10.1186/s13293-021-00372-5
29. Sun T, Warrington NM, Luo J, et al. Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males.J Clin Invest . 2014;124(9):4123-4133. doi:10.1172/JCI71048
30. Khan MT, Prajapati B, Lakhina S, et al. Identification of Gender-Specific Molecular Differences in Glioblastoma (GBM) and Low-Grade Glioma (LGG) by the Analysis of Large Transcriptomic and Epigenomic Datasets. Front Oncol . 2021;11:699594. doi:10.3389/fonc.2021.699594
31. Zhong Y, He K, Shi L, et al. Down-regulation of estrogen-related receptor alpha (ERRα) inhibits gastric cancer cell migration and invasion in vitro and in vivo. Aging . 2021;13(4):5845-5857. doi:10.18632/aging.202508
32. Zhang L, Zhu Y, Cheng H, et al. The Increased Expression of Estrogen-Related Receptor α Correlates with Wnt5a and Poor Prognosis in Patients with Glioma. Mol Cancer Ther . 2019;18(1):173-184. doi:10.1158/1535-7163.MCT-17-0782
33. Schüler-Toprak S, Weber F, Skrzypczak M, Ortmann O, Treeck O. Expression of estrogen-related receptors in ovarian cancer and impact on survival. J Cancer Res Clin Oncol . 2021;147(9):2555-2567. doi:10.1007/s00432-021-03673-9
34. Hönikl LS, Lämmer F, Gempt J, Meyer B, Schlegel J, Delbridge C. High expression of estrogen receptor alpha and aromatase in glial tumor cells is associated with gender-independent survival benefits in glioblastoma patients. J Neurooncol . 2020;147(3):567-575. doi:10.1007/s11060-020-03467-y
35. Tian M, Ma W, Chen Y, et al. Impact of gender on the survival of patients with glioblastoma. Biosci Rep . 2018;38(6):BSR20180752. doi:10.1042/BSR20180752
36. Osawa T, Tosaka M, Horiguchi K, Sugawara K, Yokoo H, Yoshimoto Y. Elderly patients aged over 75 years with glioblastoma: Preoperative status and surgical strategies. Interdiscip Neurosurg . 2021;25:101127. doi:10.1016/j.inat.2021.101127
37. Brodbelt A, Greenberg D, Winters T, et al. Glioblastoma in England: 2007-2011. Eur J Cancer Oxf Engl 1990 . 2015;51(4):533-542. doi:10.1016/j.ejca.2014.12.014